Head-to-head · WeighScore
HealthRX vs NuviaRx
By GLP-1 ScorecardUpdated
Score comparison
HealthRX has the higher recorded score — 77.5/100 to 73.5/100.
HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthRX advertises a $39 first month on three-, six- and twelve-month injection plans, with a higher month-to-month option; a plan's remaining monthly payments stay due if you cancel early.
Before you choose
Before comparing the headline prices, the HealthRX review and the NuviaRx review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, HealthRX vs Ondra Health and HelloWellness vs NuviaRx compare each of them with another graded program, and the list of alternatives to HealthRX ranks the programs closest to HealthRX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | HealthRX | NuviaRx |
|---|---|---|
| WeighScore | 77.5/100 | 73.5/100 |
| Grade | C+ | C |
| Site position | #34 | #75 |
| Semaglutide | $39 first month, then $125/month on a 3-month plan ($115 on 6 months, $97 on 12); month to month $109 first month, then $139/month | $140/mo (all doses, compounded) |
| Tirzepatide | $39 first month, then $219/month on a 3-month plan ($179 on 6 months, $159 on 12); month to month $109 first month, then $239/month | $170/mo (all doses, compounded) |
| Coverage | All 50 states claimed; subject to clinical eligibility | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- First payment and recurring monthly charge shown together for every plan
- Medication if prescribed, review, instructions and overnight shipping included; no separate GLP-1 membership fee stated
- A month-to-month option carries no minimum term
- Full refund promised if clinical approval is declined
What to consider
- On 3-, 6- and 12-month plans the remaining monthly payments stay due after an early cancellation
- Assigned medical practice and dispensing pharmacy not named on reviewed public pages
- Refund promises for unshipped doses need reconciliation with restrictions after dispensing
- Injection supplies, clinical response time and monitoring cadence unconfirmed
Strengths
- Transparent, affordable pricing — compounded semaglutide from $140/mo, tirzepatide from $170/mo
- Free delivery included; clinical evaluation and prescription bundled (if eligible)
- Full legal suite published (Terms, Privacy, HIPAA Notice, Informed Consent, Medical Disclaimer)
- Named operating entity (NuviaRx Health Inc.) with a US address and phone support
What to consider
- Compounding pharmacy partner not named ('partner pharmacy')
- LegitScript certification was not documented on the public pages reviewed
- Lowest pricing is 'as low as' — likely requires a longer prepaid plan
- State availability not published
Featured provider
HealthRX
Factor scores not reassessed.HealthRX scores 77.5/100 (C+). HealthRX advertises a $39 first month on three-, six- and twelve-month injection plans, with a higher month-to-month option; a plan's remaining monthly payments stay due if you cancel early.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.